Core Viewpoint - The Chemours Company reported a net loss of $4 million for Q1 2025, a significant decline from a net income of $54 million in the same quarter last year, indicating challenges in profitability despite a slight increase in net sales [1]. Financial Performance - The company achieved first-quarter net sales of $1,368 million, reflecting a 1.3% increase year-over-year and surpassing the Zacks Consensus Estimate of $1,355.2 million, driven by a 5% increase in volume despite a 4% drop in pricing and a 1% negative currency impact [2]. - Adjusted EBITDA for the quarter declined by 13% year-over-year to $166 million, primarily due to lower pricing across business segments, particularly in Thermal & Specialized Solutions and Titanium Technologies [3]. Segment Highlights - The Titanium Technologies division reported revenues of $597 million, a 1% increase from the previous year, exceeding the estimate of $579.2 million, attributed to a 6% increase in volumes, offset by a 4% decrease in price [3]. - The Thermal & Specialized Solutions segment saw revenues of $466 million, a 3% year-over-year increase, but fell short of the estimate of $479.2 million, with net sales growth driven by a 10% increase in volume, slightly offset by a 6% price decline [4]. - Revenues in the Advanced Performance Materials unit amounted to $294 million, a decline of approximately 3% year-over-year, yet beating the estimate of $289.4 million, with a 1% drop in volume and a 2% currency headwind [5]. Cash Flow and Capital Expenditures - Cash used by operating activities in Q1 2025 was $112 million, down from $290 million in the prior-year quarter, while capital expenditures were $84 million compared to $102 million in the previous year [6]. - The company reduced its dividend by 65% to $0.0875 per share to align with its capital allocation strategy [6]. Outlook - The company anticipates consolidated net sales to increase in the low to mid-teens sequentially in Q2, with adjusted EBITDA expected to rise by 40% to 45% [7]. - Full-year 2025 adjusted EBITDA is projected to be between $825 million and $950 million, with capital expenditures expected to range from $225 million to $275 million [7]. Stock Performance - Chemours shares have declined by 61.4% over the past year, compared to a 28.3% decline in the industry [8].

2 Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "est ...